Login to Your Account



Washington Roundup

CRS Weighs Government's Role in Drug R&D, Pricing

By Mari Serebrov
Washington Editor

Tuesday, May 1, 2012
WASHINGTON – Does the U.S. government's funding of early drug research entitle it to a say in drug pricing discussions? That question is at the center of a debate over whether the current government-academia-industry research model is out of balance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription